 "JB Chemicals surges on USFDA approval for Panoli tablet manufacturing facility")
JB Chemicals & Pharmaceuticals has moved higher by 11% to Rs 261 on the BSE after the company said its Panoli tablet manufacturing facility received approval from United States Food and Drug Administration (USFDA).
“The inspection was carried out by US FDA from June 21, 2016 to June 24, 2016 with objective to ascertain whether the company’s facility continue to meet Good Manufacturing Practices prescribed by them. We, at the end of inspection, were informed by USFDA team that their inspection ended without any critical observations, which technical terms is referred to as “Zero 483”, JB Chemicals said in a release.
At 01:19 PM, the stock was up 8% at Rs 254 on the BSE. The trading volumes on the counter jumped an over five-fold with a combined 519,498 shares changed hands on the BSE and NSE so far.
“The inspection was carried out by US FDA from June 21, 2016 to June 24, 2016 with objective to ascertain whether the company’s facility continue to meet Good Manufacturing Practices prescribed by them. We, at the end of inspection, were informed by USFDA team that their inspection ended without any critical observations, which technical terms is referred to as “Zero 483”, JB Chemicals said in a release.
At 01:19 PM, the stock was up 8% at Rs 254 on the BSE. The trading volumes on the counter jumped an over five-fold with a combined 519,498 shares changed hands on the BSE and NSE so far.